Study of Canakinumab for Fever and Joint Disease
Part of Bones, joints & muscles, Genetic & congenital, Immune system & allergy, Skin clinical trials.
This is a study looking back at patients who were already treated with a medicine called canakinumab for familial Mediterranean fever or Still's disease (rare conditions that cause fevers and joint pain). Researchers want to understand how well this medicine worked over time and what happened to patients who took it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been prescribed canakinumab before October 2021
- You took canakinumab for at least 6 months to treat familial Mediterranean fever or Still's disease
- You have medical records available for at least 3 years after you started canakinumab
- You were at least 2 years old when you started canakinumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
This study tests two new biologic medicines (goflikicept and olokizumab) as a second treatment option for people with adult-onset Still's disease. These drugs target inflammation to help control symptoms like fever, rash, and joint pain.
This study collects health information from people with adult-onset Still's disease and similar autoinflammatory conditions to better understand these diseases. By joining, you contribute to research that may lead to better care in the future.
This study tracks how well and safely canakinumab (a medication that reduces inflammation) works in patients newly diagnosed with Schnitzler's syndrome. Schnitzler's syndrome is a rare condition causing recurring fevers, rashes, and joint pain, and this study helps doctors understand how this drug performs in real-world use.
This trial tests canakinumab, a medication that blocks inflammation, given as a skin (subcutaneous) injection. It is for adults with lower-risk myelodysplastic syndromes (MDS) or a related condition (chronic myelomonocytic leukemia or CCUS) to see if it can improve blood counts and reduce problems like anemia or transfusion needs.
This trial tests if taking anakinra (a targeted medicine) only when you have a painful FMF attack can help, instead of taking it every day. It is for people with Familial Mediterranean Fever (FMF) whose attacks continue despite taking colchicine, and who do not want daily injections.
Hear when a new Still Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.